Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Functional avidity enhancement of a T-cell receptor targeting the KRASG12D cancer neoantigen.

Cellular immunology - 1 Aug 2025

Luo Feiyang, Yao Qiwen, Hao Yanan, Shen Meiying, Chen Tong, Wu Ruixin, Li Tingting, Han Xiaojian, Jin Aishun

Abstract excerpt

Engineered T cell receptors (TCRs) targeting neoantigens represent a transformative approach in cancer immunotherapy, yet their clinical potential is limited by low natural TCR avidity and the risk of off-target toxicity from over-engineered TCRs with excessive high-affinity. Here, we developed a TCR engineering platform to enhance the functional avidity of a TCR targeting the KRAS G12D mutation (KRASG12D) while...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigen-Presenting Cells
Share to Antigens, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Immunotherapy, Adoptive

Share to Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Receptors, Antigen, T-Cell

Share to T-Lymphocytes

Source

Identifiers

PMID: 40582295
DOI: 10.1016/j.cellimm.2025.104999

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Functional avidity enhancement of a T-cell receptor targeting the KRASG12D cancer neoantigen.PMID 40582295Read ↗

Identification and affinity enhancement of T-cell receptor targeting a KRASG12V cancer neoantigen.Semantic proximity Read ↗

Identification and structural characterization of a mutant KRAS-G12V specific TCR restricted by HLA-A3.Semantic proximity Read ↗

Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumorsSemantic proximity Read ↗

Identification of novel KRASG12D neoantigen specific TCRs and a strategy to eliminate off-target recognitionSemantic proximity Read ↗

Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy.Semantic proximity Read ↗

Dual-degenerate TCRs target multiple KRAS hotspot and HLA-A3 family combinationsSemantic proximity Read ↗

Chimeric Antigen Receptors Directed at Mutant KRAS Exhibit an Inverse Relationship Between Functional Potency and Neoantigen SelectivitySemantic proximity Read ↗

Identification and Structural Characterization of a mutant KRAS-G12V specific TCR restricted by HLA-A3Semantic proximity Read ↗

Therapeutic potential of T cell receptor targeting the HLA-A*11:01-restricted KRASG12V neoantigen without cross-recognition of the self-antigen RAB7B in solid tumorsSemantic proximity Read ↗

An integrated in silico-in vitro workflow for discovering high-affinity, selective antibodies to the KRAS(G12D)-MHC I complexSemantic proximity Read ↗

Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discoverySemantic proximity Read ↗

Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor–Based Cellular TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.